Background: Swedish and Danish national biologics registers have reported a possible increase in melanoma risk with TNF inhibitors. As melanomas are uncommon, the association is difficult to evaluate in other individual registers. We therefore planned a EULAR collaborative project. Methods: Patients with RA from 11 European biologics registers in 9 countries were included. Patients were followed prospectively from start of a new biologic treatment until the occurrence of first invasive histology-confirmed cutaneous melanoma, using an ever-exposed approach. For the TNFi cohort, prior exposure to biologic drugs was not permitted. Prior exposure to TNFi was allowed for other biologic drugs. For each register, incidence rates and standardized incidence ratios (SIR) of melanoma were calculated by using age-, sex-and calendar year-specific rates from the general population of the corresponding country as reference. Poisson regression models were used to summarize the register-specific SIRs to overall SIR estimates. Rates of melanoma in biologic exposed patients were compared with those in biologic-naive patients enrolled in participating registers by calculating incidence rate ratios (IRRs). Overall SIRs and IRRs were calculated, taking the size of the registers into account. Results: Overall, 114 291 patients were available for analysis: mean age 58 years; 74% female. 287 developed a first invasive melanoma.
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